An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer |
| |
Authors: | G. Hamilton M.J. Hochmair |
| |
Affiliation: | 1. Department of Surgery, Medical University of Vienna, Vienna, Austriagerhard.hamilton@toc.lbg.ac.at;3. Respiratory Oncology Unit, Otto Wagner Hospital, Vienna, Austria |
| |
Abstract: | ABSTRACTIntroduction: Brigatinib is a second-line inhibitor for the treatment of rearranged anaplastic lymphoma kinase (ALK) in lung cancer patients which has significant activity against brain metastases. This tyrosine kinase inhibitor (TKI) overcomes a wide range of ALK mutations which confer therapeutic resistance and is increasingly applied in first-line therapy due to improved benefit for patients compared to crizotinib, the current standard of care.Areas covered: The authors review the development and characteristics of brigatinib and discuss the optimal clinical use and sequence of the application of ALK inhibitors in patients progressing under therapy.Expert opinion: ALK-rearranged NSCLC can be treated with a broad range of approved and novel inhibitors at various stages of therapy, including the second-line therapeutic brigatinib. Besides this TKI, the second-line ALK inhibitors alectinib and ceritinib, as well as the third-line lorlatinib are approved for the treatment of ALK-positive NSCLC patients. The main challenge is to find sequences and combinations of ALK inhibitors which provide the best benefit for the patients. |
| |
Keywords: | Lung cancer anaplastic lymphoma kinase tyrosine kinase inhibitor brigatinib |
|
|